背景:心肌梗死(MI)后抑郁越来越普遍。肠脑轴(GBA),受肠道微生物群的影响,是理解MI后抑郁的重要组成部分。尽管肠道微生物群与MI后抑郁之间存在着良好的联系,这种关系仍然没有完全理解。
方法:本方案将遵循系统评价和荟萃分析方案(PRISMA-P)2020的首选报告项目声明。从成立到2023年10月,将对八个电子数据库进行系统搜索,包括PubMed,MEDLINE,Scopus,Embase,Cochrane临床试验数据库,WebofScience,中国国家知识基础设施,和中国生物医学文献数据库。预选研究将由两名研究人员在标准纳入后独立评估,数据提取和质量评估协议。主要结果指标是肠道微生物群的分布和抑郁症的评分量表评分的差异。当临床异质性和统计异质性都很低时,将使用固定效应模型。否则将使用随机效应模型。此外,亚组分析将使用相同的精神病学量表对参与者的抑郁严重程度进行,研究类型和地理区域。随机森林图运行和研究相关的统计分析将使用RevManV.5.3软件进行。
结果:这项研究将确定肠道菌群与MI后抑郁症发作之间的关联。并为使用益生菌作为MI后抑郁症的辅助治疗提供证据。
背景:Prospero注册号:CRD42023444026。
BACKGROUND: Depression post-myocardial infarction (MI) is becoming more prevalent. The gut-brain axis (GBA), influenced by the gut microbiota, is a critical component in understanding depression post-MI. Despite the well-established connection between gut microbiota and depression post-MI, this relationship remains incompletely understood.
METHODS: This protocol will follow the Preferred Reporting Items for Systematic Review and Meta-analysis Protocol (PRISMA-P) 2020 statement. Beginning from inception to October 2023, a systematic search will be conducted across eight electronic databases, including PubMed, MEDLINE, Scopus, Embase, Cochrane Clinical Trials Database, Web of Science, China National Knowledge Infrastructure, and China Biomedical Literature Database. Pre-selected studies will be independently assessed by two researchers following a standard inclusion, data extraction and quality assessment protocol. The primary outcome measures are differences in the profile of gut microbiota and rating scale scores for depression. Fixed-effects models will be used when both clinical heterogeneity and statistical heterogeneity are low, otherwise random-effects models will be used. Furthermore, subgroup analyses will be conducted on the depression severity of the participants using the same psychiatric scales employed, study type and geographic region. Random forest plot runs and research-related statistical analyses will be carried out using Rev Man V.5.3 software.
RESULTS: This study will identify the association between the gut microbiota and the onset of depression post-MI, and provide evidence for the use of probiotics as an adjunctive treatment for depression post-MI.
BACKGROUND: Prospero registration number: CRD42023444026.